Skip to main content

Table 2 The Los Angeles classification and Lanza scores at baseline and after treatment

From: Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study

 

Baseline

Post-treatment

p value1

Irsogladine group

   

Los Angeles classification

Grade O (16/16)

Grade O (16/16)

 

Lanza scores (stomach) (mean ± SD)

0.5 ± 1.1

0.9 ± 1.0

NS

Lanza scores (duodenum) (mean ± SD)

0.0 ± 0.0

0.4 ± 0.9

NS

Omeprazole group

  

NS

Los Angeles classification

Grade O (16/16)

Grade O (16/16)

 

Lanza scores (stomach) (mean ± SD)

0.6 ± 0.9

1.5 ± 1.1

NS

Lanza scores (duodenum) (mean ± SD)

0.0 ± 0.0

0.4 ± 0.8

0.0049

  1. 1P-values are baseline versus post-treatment within groups.